We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche Plans Actemra Response for Third Quarter
Roche Plans Actemra Response for Third Quarter
February 13, 2009
Roche has detailed the preclinical data the FDA requested in its complete response letter for Actemra, a humanized anti-human interleukin-6 receptor antibody.